JP2020517740A - 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 - Google Patents

神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 Download PDF

Info

Publication number
JP2020517740A
JP2020517740A JP2020507722A JP2020507722A JP2020517740A JP 2020517740 A JP2020517740 A JP 2020517740A JP 2020507722 A JP2020507722 A JP 2020507722A JP 2020507722 A JP2020507722 A JP 2020507722A JP 2020517740 A JP2020517740 A JP 2020517740A
Authority
JP
Japan
Prior art keywords
antibody
sequence
seq
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020507722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517740A5 (enExample
Inventor
ルウェリン レドリッチ ギャリー
ルウェリン レドリッチ ギャリー
Original Assignee
インプリシット バイオサイエンス プロプライアタリー リミティド
インプリシット バイオサイエンス プロプライアタリー リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901462A external-priority patent/AU2017901462A0/en
Application filed by インプリシット バイオサイエンス プロプライアタリー リミティド, インプリシット バイオサイエンス プロプライアタリー リミティド filed Critical インプリシット バイオサイエンス プロプライアタリー リミティド
Publication of JP2020517740A publication Critical patent/JP2020517740A/ja
Publication of JP2020517740A5 publication Critical patent/JP2020517740A5/ja
Priority to JP2023065903A priority Critical patent/JP2023090751A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020507722A 2017-04-21 2018-04-20 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 Pending JP2020517740A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023065903A JP2023090751A (ja) 2017-04-21 2023-04-13 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2017901462A AU2017901462A0 (en) 2017-04-21 Agents for treating or preventing motor neurone disease and uses therefor
AU2017901462 2017-04-21
AU2018900762 2018-03-08
AU2018900762A AU2018900762A0 (en) 2018-03-08 “agents for treating disease and uses therefor”
PCT/AU2018/050357 WO2018191786A1 (en) 2017-04-21 2018-04-20 Cd 14 antagonist antibodies for treating neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023065903A Division JP2023090751A (ja) 2017-04-21 2023-04-13 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体

Publications (2)

Publication Number Publication Date
JP2020517740A true JP2020517740A (ja) 2020-06-18
JP2020517740A5 JP2020517740A5 (enExample) 2021-05-27

Family

ID=63855469

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020507722A Pending JP2020517740A (ja) 2017-04-21 2018-04-20 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体
JP2023065903A Pending JP2023090751A (ja) 2017-04-21 2023-04-13 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023065903A Pending JP2023090751A (ja) 2017-04-21 2023-04-13 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体

Country Status (8)

Country Link
US (2) US20200148780A1 (enExample)
EP (1) EP3612566A4 (enExample)
JP (2) JP2020517740A (enExample)
KR (1) KR20200015477A (enExample)
CN (1) CN110831975A (enExample)
AU (1) AU2018255489B2 (enExample)
IL (2) IL270097B2 (enExample)
WO (1) WO2018191786A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021523375A (ja) * 2018-05-10 2021-09-02 ザ・メソジスト・ホスピタル 疾病の予後と管理のための方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso
TWI877170B (zh) * 2019-06-11 2025-03-21 美商阿列克特有限責任公司 抗揀選蛋白抗體之使用方法
JP2022541646A (ja) * 2019-07-25 2022-09-26 インプリシット・バイオサイエンス・リミテッド 急性神経炎症傷害を処置するための方法および薬剤
CN115103676A (zh) * 2020-02-13 2022-09-23 普瑞尼亚神经治疗有限公司 使用普利多匹定和另一种激活剂治疗肌萎缩侧索的组合疗法
EP4092051A4 (en) * 2020-06-18 2023-09-06 Shenzhen Mindray Bio-Medical Electronics Co., Ltd SOLUBLE ANTI-SUBTYPE CD14 ANTIBODY, KIT AND CORRESPONDING USE
IL301762A (en) 2020-10-07 2023-05-01 Line 6 Biotechnology Inc Methods and materials for the treatment of eye diseases
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117031014A (zh) * 2023-08-14 2023-11-10 陕西脉元生物科技有限公司 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN118290585B (zh) * 2024-06-04 2024-08-30 苏州为度生物技术有限公司天津分公司 一种抗人cd14工程抗体及应用
CN120399098B (zh) * 2025-07-03 2025-09-16 上海玄言生物科技有限公司 抗cd14抗体-il-15超级激动剂融合蛋白及其制法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI920450A7 (fi) * 1989-08-01 1992-01-31 Scripps Clinic And Res Foundation Menetelmiä ja koostumuksia verenmyrkytyksen oireiden estämiseksi
ATE335072T1 (de) * 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
DE69534601T2 (de) * 1994-09-16 2006-08-03 The Scripps Research Institute, La Jolla Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
WO2002042333A1 (en) 2000-11-22 2002-05-30 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
CA2590284A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
US20090181008A1 (en) * 2005-11-10 2009-07-16 Satoris, Inc. Methods of treating alzheimer's disease
KR101256837B1 (ko) * 2009-03-09 2013-04-22 경북대학교 산학협력단 가용성 ｃｄ１４의 파킨슨 병 진단 및 치료용 용도
JP5894939B2 (ja) * 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
WO2018165720A1 (en) * 2017-03-17 2018-09-20 Implicit Bioscience Pty Ltd Agents for treating or preventing viral infections and uses therefor
WO2019217916A1 (en) * 2018-05-10 2019-11-14 The Methodist Hospital Methods for prognosis and management of disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ACTA MYOLOGICA, vol. 30, JPN6022016701, 2011, pages 4 - 8, ISSN: 0005085089 *
EXPERIMENTAL NEUROLOGY, vol. 273, JPN6022016704, 2015, pages 24 - 35, ISSN: 0005085088 *
GLIA, vol. 58, JPN6022016699, 2010, pages 231 - 243, ISSN: 0005085091 *
JOURNAL OF CLINICAL IMMUNOLOGY, vol. 23, JPN6022016700, 2003, pages 132 - 140, ISSN: 0005085090 *
MEDICINE, vol. 100, JPN6022052942, 2021, pages 27421, ISSN: 0005085092 *
NEUROSCIENCE, vol. 158, JPN6023025125, 2009, pages 896 - 903, ISSN: 0005085093 *
TRENDS IN BIOTECHNOLOGY, vol. 34, JPN6023025124, 2016, pages 36 - 48, ISSN: 0005085094 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021523375A (ja) * 2018-05-10 2021-09-02 ザ・メソジスト・ホスピタル 疾病の予後と管理のための方法
JP7371019B2 (ja) 2018-05-10 2023-10-30 ザ・メソジスト・ホスピタル 疾病の予後と管理のための方法

Also Published As

Publication number Publication date
JP2023090751A (ja) 2023-06-29
CN110831975A (zh) 2020-02-21
IL309046A (en) 2024-02-01
AU2018255489B2 (en) 2024-06-13
US20220010025A1 (en) 2022-01-13
AU2018255489A1 (en) 2019-11-07
EP3612566A1 (en) 2020-02-26
IL270097B1 (en) 2024-01-01
IL309046B2 (en) 2025-03-01
US12297287B2 (en) 2025-05-13
EP3612566A4 (en) 2021-03-03
IL270097A (enExample) 2019-12-31
IL309046B1 (en) 2024-11-01
IL270097B2 (en) 2024-05-01
WO2018191786A1 (en) 2018-10-25
US20200148780A1 (en) 2020-05-14
KR20200015477A (ko) 2020-02-12

Similar Documents

Publication Publication Date Title
US12297287B2 (en) CD14 antagonist antibodies for treating neurodegenerative diseases
JP7730936B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
JP7554247B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
JP7480197B2 (ja) 抗ｔｒｅｍ１抗体及びその使用方法
US11926671B2 (en) Antibodies and polypeptides directed against CD127
KR20210025614A (ko) 항-sirp-베타1 항체 및 그의 사용 방법
KR20230005848A (ko) 항-trem2 항체의 사용 방법
JP7678802B2 (ja) Ｓｉｇｌｅｃ－９ＥＣＤ融合分子及びその使用方法
EP3082863B1 (en) Alpha-enolase specific antibodies and method of use in immune diseases
TW202241945A (zh) 類固醇節制
JP2025508757A (ja) 抗ｔｒｅｍ２抗体の使用方法
HK40087465A (zh) 抗trem2抗体的使用方法
EA044134B1 (ru) Анти-trem2 антитела и способы их применения

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20191127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220809

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230413

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230413

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230425

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230609

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250502